Sansure Biotech (SHSE:688289) Cash-to-Debt : 11.61 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sansure Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sansure Biotech's cash to debt ratio for the quarter that ended in Mar. 2024 was 11.61.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sansure Biotech could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Sansure Biotech's Cash-to-Debt or its related term are showing as below:

SHSE:688289' s Cash-to-Debt Range Over the Past 10 Years
Min: 9.94 Med: 214.7 Max: No Debt
Current: 11.61

During the past 7 years, Sansure Biotech's highest Cash to Debt Ratio was No Debt. The lowest was 9.94. And the median was 214.70.

SHSE:688289's Cash-to-Debt is ranked better than
74.61% of 831 companies
in the Medical Devices & Instruments industry
Industry Median: 1.89 vs SHSE:688289: 11.61

Sansure Biotech Cash-to-Debt Historical Data

The historical data trend for Sansure Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sansure Biotech Cash-to-Debt Chart

Sansure Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

69.22

314.34

203.32

124.81

Sansure Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															243.22	197.33	235.89	124.81	11.61

Competitive Comparison of Sansure Biotech's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Sansure Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sansure Biotech's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sansure Biotech's Cash-to-Debt falls into.

Sansure Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sansure Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4781.767	/	(20.101	+	18.211)
	=	124.81

Sansure Biotech's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4948.031	/	(19.919	+	406.168)
	=	11.61

Sansure Biotech (SHSE:688289) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Sansure Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sansure Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sansure Biotech (SHSE:688289) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sansure Biotech Inc (SHSE:688289) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205

Website

http://www.sansure.com.cn

Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.

Sansure Biotech (SHSE:688289) Headlines

No Headlines